Synairgen is a specialist respiratory biotech company whose primary focus is developing our investigative candidate SNG001 (inhaled interferon beta) to meet the urgent need for the treatment of COVID-19 and other severe viral lung infections as potentially the first host-targeted broad-spectrum antiviral treatment delivered directly into the lungs. Our Phase 3 clinical trial is currently evaluating nebulised SNG001 in hospitalised COVID-19 patients across 17 countries. In a Phase 2 trial in hospitalised COVID-19 patients, SNG001 demonstrated a greater than twofold chance of recovery to ‘no limitation of activities’ versus placebo. Founded by University of Southampton (UK) Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003, Synairgen is quoted on AIM (LSE: SNG). For more information, please visit www.synairgen.com.